Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.

A Phase III hit moves atrasentan a step closer to the market but the drug will have to sell very well to justify the billions Novartis paid for its originator.

A very early success with a gene therapy for a rare form of deafness puts Regeneron ahead of Lilly and Sensorion.

Hanmi aims to commercialize its GLP-1 obesity treatment, the first one from its ambitious HOP project, within three years as it moves to Phase III in Korea.